Entinostat plus ZEN003694 for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older with an advanced or treatment-resistant solid tumor (Phase 2 focuses on unresectable or metastatic pancreatic cancer).
- For solid tumors, you have measurable disease on a scan (RECIST 1.1) and you’ve already had at least one standard metastatic treatment regimen.
- Your recent health tests are strong enough: hemoglobin ≥ 9, neutrophils (ANC) ≥ 1,500, platelets ≥ 100,000, and blood counts/coagulation within required ranges.
- Your organs can handle treatment: bilirubin, AST/ALT, kidney function (GFR), and albumin meet study limits.
- You must be able to take pills by mouth and be stable enough to do daily activities (ECOG performance status 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
This trial is testing a new drug called AST-001 for people with advanced solid tumors (including pancreatic cancer) that have not responded to standard treatments. The study aims to find the right dose and see how well the drug works.
This study tests whether adding an experimental drug called entinostat to standard chemotherapy can help people with advanced bladder cancer whose first treatment has stopped working. It aims to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Refractory Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.